GlassScriptPhysician profile
George Aguiar
NPI 1750308086
$126,700.81
in general payments reported to CMS, 2019-2025
14 companies · $471 in 2025
The $471 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,338 · 2020: $163 · 2021: $492 · 2022: $121K · 2023: $520 · 2024: $712 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,681 · Education: $21.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,681.08 |
| Education | $21.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Anika Therapeutics, INC. | $119,515.40 | 2022 | |
| Stryker Corporation | $3,268.43 | 2019-2025 | Mako, Orthomap |
| Smith+Nephew, INC. | $2,214.64 | 2019-2025 | Bone Anchors With Arthroscopic Delivery System, Healicoil, Na |
| Supreme Orthopedic Systems, LLC | $1,301.00 | 2022-2025 | |
| Djo, LLC | $140.37 | 2019 | |
| Molnlycke Health Care US, LLC | $52.06 | 2022 | |
| Acumed LLC | $44.26 | 2024 | Acumed, Osteomed |
| Innovation Technologies INC | $34.44 | 2022 | |
| Bioventus LLC | $32.01 | 2024 | Durolane |
| Heron Therapeutics, INC. | $28.68 | 2024 | Zynrelef |
| Depuy Synthes Sales INC. | $22.19 | 2019 | |
| Vericel Corporation | $21.37 | 2023 | Maci |
| Pacira Pharmaceuticals Incorporated | $13.49 | 2019 | |
| Dynasplint Systems INC. | $12.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Aguiar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.